Beefed-up CAR T cells. Applying dual-antigen targeting (either BCMA/SLAMF7 or BCMA/FAP) inhibits CAFs in the tumor microenvironment and, thus, increases the anti–multiple myeloma (anti-MM) efficacy of CAR T cells that target BCMA.
Beefed-up CAR T cells. Applying dual-antigen targeting (either BCMA/SLAMF7 or BCMA/FAP) inhibits CAFs in the tumor microenvironment and, thus, increases the anti–multiple myeloma (anti-MM) efficacy of CAR T cells that target BCMA.